The plasma protein treatment cycle is complicated and closely monitored to ensure process efficacy and safety donor safety, biological licensing, compliance, and pharmacovigilance. The global need for immunoglobulin is rising due to an increase in the prevalence of primary immunodeficiencies (PID). As a result, the number of clinical applications has risen, including autoimmune and acute inflammatory illnesses.
The market for plasma protein therapeutics will grow at a strong CAGR of 7.1%, from a value of $27.20 billion in 2021 to $50.4 billion by 2030.
The global market for plasma protein therapies is very competitive and subject to strict restrictions. In developed regions, plasma collection standards are excellent, and a tight regulatory structure is in place to preserve operational quality. Health authorities monitor the fractionation process to prevent poor plasma quality and guarantee that the source plasma is free of infectious agents like Parvovirus B, hepatitis A, B, and C, and HIV.
Due to the plasma protein’s useful features, the market is now experiencing an increased demand for sophisticated therapeutic treatments, fueling the industry’s expansion. Additionally, the government supports the development of the healthcare sector and the favorable reimbursement practices of health insurance investment firms, fueling the market’s expansion. The development of plasma protein therapies and the production of sophisticated delivery systems for these treatments, combined with ongoing technological improvements in the extraction and separation of plasma, are driving the worldwide plasma protein therapeutics market.
The implementation of plasma therapy may be hampered by the imposition of rigid guidelines and rules for handling plasma protein products and by the absence of reimbursement plans. These main factors hinder the market for plasma protein therapies from expanding.
In the coming years, opportunities may arise as people become more aware of autoimmune diseases (such as Von Willebrand disease, antithrombin III deficiency, cardiopulmonary disease, chronic inflammatory demyelinating polyneuropathy, and hepatitis), organ transplants (such as liver surgery and pediatric HIV), and cases of burns that result in trauma among people.
The plasma protein therapies market is divided into albumin, immunoglobulins (IG), plasma-derived factor VIII, and others based on the kind of product. Immunoglobulin took the top spot in 2021 with a market share of more than 45.42%. The widespread acceptance of biologics for various purposes, simplicity of administration, and high cost of care are all to blame for the high percentage.
The enhanced detection of hypoalbuminemia brought on by liver cirrhosis and hepatitis B is predicted to contribute to the albumin segment’s large market growth during the projection period. As albumin’s largest market, China’s high demand and consumption are expected to enhance the expansion.
In 2020, the Haemophilia sector held the greatest market share of around 45%. More than 1,125,000 men worldwide suffer from an inherited bleeding illness, and 418,000 of them have a severe form of the most underdiagnosed disease, according to the Global Hemophilia Care report. Factors like the rising number of life-threatening diseases, the growing geriatric population, changes in dietary habits, and the adoption of a sedentary lifestyle are driving the segment’s overall expansion.
North America and Europe account for around 70.26% of the market. The U.S. led the North American market with a share of more than 40.47% in 2021. Some of the important geographical drivers include the presence of a sizable patient base, an increasing geriatric population, and the availability of a well-developed infrastructure for storing and keeping high-quality source plasma. Some other major regional expansion drivers include rising disease prevalence and increased use of innovative therapies.
- Grifols, SA
- Biotest AG
- CSL Behring
- Takeda Pharmaceutical Company Ltd
- Octapharma USA Inc.
- Octapharma USA Inc.
- Shrie Plc
- China Biologic Products Holdings Inc.
- al Company Ltd
- Grifols SA
The market for plasma protein therapies will grow at a strong CAGR of 7.1%, from a value of $27.20 billion in 2021 to $50.4 billion by 2030. The primary driver of the growth of the global plasma protein therapeutics market is the rising demand for plasma protein therapeutics for the treatment of autoimmune neurologic diseases, acute cardiomyopathy, multifocal motor neuropathy (MMN), hemolytic disease of the newborn, autoimmune mucocutaneous blistering diseases, and acute panautonomic polyneuropathy.